Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Tirzepatide was developed as a unimolecular dual agonist and moved through the SURPASS (type 2 diabetes) and SURMOUNT (obesity) Phase 3 programs to approval, becoming the first approved GLP-1/GIP dual agonist
Love the service everything was perfect
Reconstitute the lyophilized powder using the diluent recommended by your provider, then store and handle the solution as instructed to protect peptide stability
What it adds A GHRH signal that raises the body's own GH and IGF-1 activity
US$ 29.62
US$ 24.16
US$ 27.15
US$ 20.35
